IX

Global Digital Vehicles Top Technology Trends Report 2023-2040: New Automotive Applications of Blockchain Technologies to Advance Automated, Connected, Electric Driving and Sustainability

Retrieved on: 
星期四, 三月 9, 2023
Electronics, Software, Digital, Original equipment manufacturer, Communication, 2600-series (CTA), Digital twin, Ecosystem, Internet, Computing, Machine learning, Cyberattack, Big data, HMI, Build automation, Internet of things, Architecture, Investment, Policy, Sustainability, OTA, Écu, Data, IX, Satellite navigation device, Cryptocurrency, Video game, Arms industry, AI, Electrification

The report unveils new automotive applications of blockchain technologies to advance automated, connected, electric driving and sustainability

Key Points: 
  • The report unveils new automotive applications of blockchain technologies to advance automated, connected, electric driving and sustainability
    5G connectivity, Vehicle-to-Everything (V2X) communications, AI, Software and Big data are driving the digital transformation of the automotive industry.
  • Connectivity advancements are pushing for more dedicated software development, while a large part of hardware-oriented systems becomes more standardized and commoditized.
  • Next-generation autonomous vehicles must integrate new, diverse technologies and complex logical operations; the hardware architecture has to support advanced software functionality and upgradability.
  • The majority of carmakers and major automotive suppliers are working on Software-Defined Vehicles, such as APTIV with their Smart Vehicle Architecture.

CSL's HOPE-B Data Published in the New England Journal of Medicine, Demonstrating Efficacy and Durability of HEMGENIX® (etranacogene dezaparvovec-drlb)

Retrieved on: 
星期四, 二月 23, 2023
Medicine, Development, University, Headache, Safety, Civil service commission, Research and development, IX, Pediatrics, MD, EC, European, Pathology, Vol, European Economic Area, ASX, Research, The New England Journal of Medicine, Factor IX, FDA, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Haemophilia, Coagulopathy, Hematology, Nausea, Fatigue, CSL, NEJM, ABR, Blood, Professor, European Commission, Food, Medical device, Vaccine, Pharmaceutical industry

8) results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb).

Key Points: 
  • 8) results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb).
  • Increased factor IX activity was also apparent from week 3 and maintained over 18 months.
  • Annualized factor IX infusions also significantly decreased from 72.5 infusions per participant during lead-in period (95% CI: 63.6, 82.7) to 2.5 infusions (95% CI: 0.92, 6.96) post-treatment.
  • CSL remains steadfast in our commitment to deliver on our promise of innovation for people living with rare bleeding disorders."

uniQure Announces HOPE-B Clinical Trial Data Published in the New England Journal of Medicine, Demonstrating Durability and Other Benefits of HEMGENIX® (etranacogene dezaparvovec-drlb)

Retrieved on: 
星期四, 二月 23, 2023
Medicine, University, Headache, Safety, Civil service commission, Pediatrics, IX, Quality of life, EC, European, Pathology, Vol, ASX, The New England Journal of Medicine, Factor IX, Research, FDA, Patient, ALT, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Haemophilia, Doctor of Philosophy, Fatigue, CSL, NEJM, ABR, AST, European Commission, Professor, Incidence, Food, Pharmaceutical industry, Vaccine, Medical device

LEXINGTON, Mass. and AMSTERDAM, Feb. 23, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL) today announced the publication in the New England Journal of Medicine (NEJM) (Vol. 388 No. 8) of results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb). HEMGENIX® is the first and only gene therapy approved for the treatment of adults with hemophilia B who currently use factor IX prophylaxis therapy, or have current or historical life-threatening bleeding, or have repeated, serious spontaneous bleeding episodes. 

Key Points: 
  • 8) of results from the pivotal HOPE-B clinical study evaluating the efficacy, durability and safety of HEMGENIX® (etranacogene dezaparvovec-drlb).
  • The multi-year clinical development of HEMGENIX® was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialize the treatment.
  • Annualized factor IX infusions also significantly decreased from 72.5 infusions per participant during lead-in period (95% CI: 63.6, 82.7) to 2.5 infusions (95% CI: 0.92, 6.96) post-treatment.
  • uniQure is immensely proud to have led the multi-year clinical development program for HEMGENIX® that included the HOPE-B pivotal trial.”

uniQure announces the European Commission approval of the first gene therapy for adults with hemophilia B

Retrieved on: 
星期二, 二月 21, 2023
Joint, Science, Medication, European Commission, CSL, United Kingdom, CMA, IX, Medicine, Haemophilia, Factor IX, Civil service commission, Patient, Liver, European Economic Area, Food, Research, ASX, Risk, CSL Behring, Health care, Disease, Partnership, Bleeding, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Haemophilia B, Quality of life, ABR, Teaching hospital, Pharmaceutical industry, Medical device, Dietary supplement, EEA, EU, European

LEXINGTON, Mass. and AMSTERDAM, Feb. 21, 2023 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, announced that its partner, global biotechnology leader CSL (ASX: CSL), has received conditional marketing authorization (CMA) from the European Commission for HEMGENIX® (etranacogene dezaparvovec), the first and only one-time gene therapy for the treatment of severe and moderately severe hemophilia B.

Key Points: 
  • It is the first approved gene therapy for hemophilia B in the European Union (EU) and European Economic Area (EEA).
  • “The European approval of HEMGENIX represents another major milestone in the field of genomic medicine and innovation in the treatment of people living with hemophilia B,” said Matt Kapusta , chief executive officer of uniQure.
  • Treatments for moderate to severe hemophilia B include prophylactic infusions of factor IX replacement therapy to temporarily replace or supplement low levels of blood-clotting factor and, while these therapies are effective, those with hemophilia B must adhere to strict, lifelong infusion schedules.
  • uniQure conducted the research and clinical development for the product, which included three clinical trials across 34 global sites and involving 67 adults with hemophilia B.

Eightfold AI Brings Consumer-grade Interactivity, Speed and Relevance to All Talent Processes with its Intelligent Experience (IX) Interface

Retrieved on: 
星期二, 二月 14, 2023
Organization, Workflow, Celebrate, Threat Intelligence Platform, AI, IX, Customer service, Eightfold path (policy analysis)

SANTA CLARA, Calif., Feb. 14, 2023 /PRNewswire/ -- Eightfold AI, the leader in AI-powered talent intelligence, today announced the rollout of its Intelligent Experience (IX) offering across its entire Talent Intelligence Platform. This new experience is designed from the ground up to better cater to users' needs, optimize and personalize recommendations, greatly improve the look and feel of Eightfold's platform, and dramatically increase the adoption of AI into all talent processes. The resulting experience allows Eightfold customers to focus on data-driven, high fidelity activities and the decisions that matter most.

Key Points: 
  • The next step for talent software: straightforward, seamless integration of sophisticated AI
    SANTA CLARA, Calif., Feb. 14, 2023 /PRNewswire/ -- Eightfold AI , the leader in AI-powered talent intelligence, today announced the rollout of its Intelligent Experience (IX) offering across its entire Talent Intelligence Platform.
  • The resulting experience allows Eightfold customers to focus on data-driven, high fidelity activities and the decisions that matter most.
  • "With the new Eightfold Intelligent Experience, customers can enjoy a simplified platform experience that better contextualizes Eightfold's AI features and recommendations, enabling them to scale those talent processes with advanced accuracy."
  • Eightfold IX will be distributed in 2023, with the first phase of enhancements already available for all Eightfold customers.

BDx to Develop a New 16MW Data Center in Hong Kong's Emerging Kwai Chung District

Retrieved on: 
星期四, 二月 2, 2023
Intelligence, Government, IX, Investment, The Digital Hub, Industrialisation, Connectivity, Heart, Sino Group, ICT, Growth, Tutoring, Film industry

HONG KONG, Feb. 1, 2023 /PRNewswire/ -- Big Data Exchange (BDx), the fastest growing carrier-neutral data center platform in Asia-Pacific, has announced its plan to develop a new 16MW facility in the upcoming high-tech industrial area being developed by Sino Group, a leading property developer in Hong Kong. BDx is targeting to get the hyperscaler-ready data center, which is called HKG8, operational by end 2023.

Key Points: 
  • BDx is targeting to get the hyperscaler-ready data center, which is called HKG8, operational by end 2023.
  • This is BDx's fourth data center in Hong Kong and will be located in the heart of the Kwai Chung District, which is rapidly transforming into a highly sought-after industrial and commercial zone.
  • The data center is strategically located five kilometers from the nearest port and 26 kilometers from the Hong Kong airport.
  • "BDx is pleased to announce our new data center to further our commitment to the Hong Kong market.

OPTAGE Builds Its Fifth Data Center in Osaka, Japan

Retrieved on: 
星期三, 一月 25, 2023
Environment, Technology, Security, Utilities, Telecommunications, Alternative Energy, Green Technology, Energy, Data Management, Wind, CO2, Natural Resources, AI, IX, Internet of things, Electricity, Water, Internet service provider, Computer data storage

OPTAGE's highly reliable fiber optic links directly to these data centers, enabling clients to communicate with stability and low latency.

Key Points: 
  • OPTAGE's highly reliable fiber optic links directly to these data centers, enabling clients to communicate with stability and low latency.
  • In addition, data center providers can take advantage of OPTAGE's rich fiber optics to provide a variety of network services.
  • The non-fossil certificate with tracking will ensure that all electricity used by the data center is generated by natural resources such as solar, wind and water.
  • We will actively work to reduce CO2 emissions and aim to become a carbon-neutral green data center that is environmentally friendly.

Polygon's Biggest P2E Game, Planet IX Records Staggering Growth on BitKeep NFT Market

Retrieved on: 
星期五, 二月 10, 2023
Blockchain, BitKeeper, OKX, NFT, Planet Nine, Non-fungible token, YORK, Sale, P2E, Growth, BNB, Decentralized finance, IX, Cryptocurrency, Polygon

As of 9 February 2023, Planet IX's monthly transaction volume was $840K, with 77% generated from the BitKeep NFT market.

Key Points: 
  • As of 9 February 2023, Planet IX's monthly transaction volume was $840K, with 77% generated from the BitKeep NFT market.
  • Planet IX is undoubtedly a rising star in both BitKeep NFT Market and the Polygon NFT market.
  • Planet IX’s NFT transaction volume on BitKeep NFT Market is greater than that of the closest competitors OKX and OpenSea, by a factor of 120x and 4x respectively.
  • The growth of Planet IX on BitKeep is a testament to the platform's value for the P2E community.

EQT AB (publ) Year-end Report 2022

Retrieved on: 
星期三, 一月 18, 2023
Partner (business rank), Person, Sustainability, Recipharm, Total, CR, Growth, Capital, Sale, Business, CPP Investment Board, Chairperson, Communication, FTE, BPEA, EQT, Executive Committee, EUR, 7M, RCF, Popular Executive Committee of Valencia, AUM, United Talent Agency, Annual report, EQT Ventures, Webcast, Business development, IX, EQT Partners, USD, Investment, SEK, Foreign policy, Wealth, LSP, EU, Film, Bank, Financial services, Management, Renewable energy, Holding company

STOCKHOLM, Jan. 18, 2023 /PRNewswire/ -- "EQT concluded 2022 – a transformative year – as a global leader in active ownership. We relentlessly continue to future-proof our expanding platform, while navigating macroeconomic and geopolitical uncertainty," expressed Christian Sinding, CEO and Managing Partner, EQT Partners AB.

Key Points: 
  • We relentlessly continue to future-proof our expanding platform, while navigating macroeconomic and geopolitical uncertainty," expressed Christian Sinding, CEO and Managing Partner, EQT Partners AB.
  • The fund was activated in December 2022, with EUR 2.8bn raised by year-end 2022.
  • In addition, a half-year report and a year-end report including financial statements and further information relevant for investors is published.
  • This is information that EQT AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.

Arelion Expands Network Coverage in APAC, Adds New PoP in Osaka, Japan

Retrieved on: 
星期四, 一月 12, 2023
Cloud, Google Cloud Connect, Internet, Internet exchange point, DDoS mitigation, PTC, Pop, IX, Equinix, Internet service provider

HONOLULU, and STOCKHOLM, N.Y., Jan. 12, 2023 /PRNewswire/ -- PTC '23 -- Arelion (formerly Telia Carrier) today announced a new Point-of-Presence (PoP) in Osaka, Japan.

Key Points: 
  • HONOLULU, and STOCKHOLM, N.Y., Jan. 12, 2023 /PRNewswire/ -- PTC '23 -- Arelion (formerly Telia Carrier) today announced a new Point-of-Presence (PoP) in Osaka, Japan.
  • Arelion recently announced global 40G Ethernet Virtual Circuit (VC) availability and will offer this key product in its new PoP to facilitate digital transformation in Asian markets.
  • The new PoP strengthens the region's connection to the international market and enhances scalable connectivity options across the APAC region.
  • "The new PoP in Osaka is another important step in our global expansion strategy," said Wee Kwan Ee, Head of Sales APAC, Arelion.